STAT+: Pharmalittle: We’re reading about FDA staff fears, a Lilly weight loss drug and much more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still coming together. We plan to catch up on our reading, spend time with one of the short people and observe an […]
STAT+: Pharmalittle: We’re reading about Lilly’s new obesity drug, E.U. pharma rules, and much more
Top of the morning to you, and a fine one it is. Although quite chilly so far, the clear, blue skies and warm sunshine are a heartening elixir for a busy day ahead. To cope, we are brewing fresh cups of stimulation. Our choice today is chocolate raspberry. As always you are invited to join […]
STAT+: Lilly’s next-gen obesity drug delivers major weight loss in Phase 3 trial, but with many discontinuations
Eli Lilly’s next-generation obesity drug led to what appears to be the most weight loss seen so far in a late-stage trial, but rates of side effects were high and many participants discontinued the treatment, including people who felt they were losing too much weight. In a 68-week Phase 3 study of patients with obesity […]
STAT+: Wave’s ‘gym bro’ obesity drug is story over substance
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. I’m just back from the ASH meeting in Orlando, so a shorter-than-normal newsletter this week. “Mean Adam” is also back. You’ll see below. Continue to STAT+ to read the full story…
STAT+: Driven by GLP-1s, prescription drug spending explodes at major health insurers
Health insurance companies have lamented fast-rising medical expenses for more than two years. This year is no different as Americans continue to get more care than insurers expected. One of the main culprits of that higher spending: prescription drugs, and GLP-1s in particular. Some insurers spent more on drugs in the first nine months of […]
STAT+: New data confirm Novo drug did not slow Alzheimer’s progression
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got a lot of biotech news to get to today. STAT is also launching a 10-part series called “American Science, Shattered” today. You can read the first few stories here. Continue […]
Opinion: Public health should embrace GLP-1 drugs without abandoning obesity prevention
Following the White House’s recent announcement of price reductions and expanded coverage for GLP-1 medications like Wegovy and Zepbound, many patients searching for obesity treatments are about to gain access to highly effective options. The implications for U.S. public health are vast. Read the rest…
Pharmalittle: We’re reading about failed Novo Alzheimer’s trials, favorable Bayer stroke results, and more
Good morning, Jason Mast here filling in for Ed. Happy turkey week to all. I, for one, have always detested that dry, tasteless bird. (It’s sides and brisket for me, followed by pecan pie.) So in their interest, I leave you with this story, from 2018, about the Ozark turkeys that fell from the sky. […]
STAT+: Novo Nordisk’s semaglutide fails to slow Alzheimer’s progression
Two trials testing the Novo Nordisk weight loss drug semaglutide in Alzheimer’s disease failed, the company said Monday, showing the medicine did not slow the progression of the condition versus placebo. Studying semaglutide — the key ingredient in the blockbusters Ozempic and Wegovy — in Alzheimer’s was always seen as a long shot, even as […]
STAT+: Why is Eli Lilly worth nearly $1 trillion?
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got big FDA news to get into today — let’s get straight into it. FDA names Richard Pazdur as top drug regulator The FDA yesterday said it has chosen Richard Pazdur, its […]